background
still
effect
method
prevent
treat
sever
acut
respiratori
syndrom
sar
caus
sar
coronaviru
cov
present
studi
evalu
efficaci
fulli
human
monoclon
antibodi
capabl
neutral
sarscov
vitro
rhesu
macaqu
model
sar
method
antibodi
obtain
vaccin
km
mice
bear
human
immunoglobulin
gene
escherichia
coliproduc
recombin
peptid
contain
domin
epitop
viral
spike
protein
found
convalesc
serum
sampl
patient
sar
result
recogn
epitop
also
cleavag
site
critic
entri
sarscov
host
cell
inhibit
propag
viru
patholog
chang
found
rhesu
macaqu
infect
viru
nasal
rout
addit
analyz
mode
action
result
suggest
inhibit
fusion
viru
envelop
host
cell
membran
potenti
use
prevent
treatment
sar
reemerg
conclus
studi
repres
platform
produc
fulli
human
antibodi
emerg
infecti
diseas
time
safe
manner
background
still
effect
method
prevent
treat
sever
acut
respiratori
syndrom
sar
caus
sar
coronaviru
cov
present
studi
evalu
efficaci
fulli
human
monoclon
antibodi
capabl
neutral
sarscov
vitro
rhesu
macaqu
model
sar
method
antibodi
obtain
vaccin
km
mice
bear
human
immunoglobulin
gene
escherichia
coliproduc
recombin
peptid
contain
domin
epitop
viral
spike
protein
found
convalesc
serum
sampl
patient
sar
result
recogn
epitop
also
cleavag
site
critic
entri
sarscov
host
cell
inhibit
propag
viru
patholog
chang
found
rhesu
macaqu
infect
viru
nasal
rout
addit
analyz
mode
action
result
suggest
inhibit
fusion
viru
envelop
host
cell
membran
potenti
use
prevent
treatment
sar
reemerg
conclus
studi
repres
platform
produc
fulli
human
antibodi
emerg
infecti
diseas
time
safe
manner
sever
acut
respiratori
syndrom
sar
observ
countri
affect
person
result
death
case
diseas
caus
newli
identifi
sar
coronaviru
cov
although
bat
carri
virus
similar
sarscov
natur
host
yet
identifi
vaccin
drug
treatment
yet
approv
thu
still
risk
reemerg
sar
human
popul
necessari
develop
effect
measur
combat
diseas
sarscov
enter
host
cell
mechan
involv
interact
spike
protein
human
angiotensinconvert
enzym
express
host
cell
lung
entri
cleav
ntermin
region
ctermin
region
mediat
bind
mediat
fusion
viral
host
cell
membran
region
name
studi
correspond
amino
acid
posit
contain
cleavag
site
domain
also
contain
epitop
recogn
serum
sampl
convalesc
patient
sar
vietnam
protein
also
play
import
role
induc
protect
immun
antibodi
target
domain
howev
also
induc
antibodydepend
enhanc
sarscov
entri
host
cell
amino
acid
sequenc
protein
chang
monoclon
antibodi
sarscov
gener
human
murin
background
monoclon
antibodi
mab
test
passiv
immun
mice
ferret
hamster
show
abil
prevent
limit
infect
vivo
evalu
mab
perform
model
lack
detect
clinic
symptom
diseas
difficult
assess
whether
antibodi
test
would
actual
provid
reason
protect
human
rhesu
macaqu
one
valuabl
tool
evalu
efficaci
antibodi
sarscov
model
show
viru
propag
immunolog
respons
patholog
chang
lung
infect
anim
present
studi
produc
fulli
human
monoclon
antibodi
immun
km
mice
produc
human
antibodi
fragment
deriv
sarss
protein
prepar
escherichia
coli
sarscov
obtain
human
antibodi
capabl
neutral
viru
examin
neutral
activ
sarscov
vivo
rhesu
macaqu
sar
model
recombin
protein
supplement
fig
express
histag
protein
use
tagzym
vector
qiagen
affin
purifi
use
tag
tag
protein
remov
enzymat
describ
elsewher
use
vaccin
anim
anim
experi
perform
accord
guidelin
ethic
review
committe
anim
experi
intern
medic
center
japan
aliquot
lg
purifi
proteinsanim
use
vaccin
rabbit
km
mice
transgen
anim
produc
fulli
human
antibodi
freund
adjuv
difco
laboratori
produc
human
monoclon
antibodi
spleen
cell
km
mice
vaccin
fragment
fuse
mous
myeloma
cell
line
hybridoma
screen
abil
bind
recombin
protein
convent
enzymelink
immunosorb
assay
describ
elsewher
mass
product
perform
fedbatch
cultur
cho
cell
describ
elsewher
epitop
map
mab
perform
use
set
overlap
peptid
puriti
span
entir
sequenc
protein
consist
amino
acid
overlap
next
peptid
amino
acid
describ
elsewher
experi
use
sarscov
perform
level
facil
neutral
activ
mab
sarscov
determin
plaqu
reduct
assay
monolay
vero
cell
grown
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
plate
carbon
dioxid
sampl
ml
incub
equal
volum
sarscov
suspens
contain
plaqueform
unit
viru
water
bath
h
sampl
incub
mixtur
use
infect
vero
monolay
adsorpt
h
cultur
overlaid
methylcellulosecontain
media
incub
day
cell
fix
formalin
stain
crystal
violet
citric
acid
irradi
uv
light
h
dri
number
viru
plaqu
count
neutral
titer
defin
reciproc
dilut
serum
caus
reduct
plaqu
count
compar
neg
control
neutral
assay
sarscov
cell
monolay
stain
neutral
red
sigma
dmem
h
wash
acid
alcohol
acet
acid
ethanol
ad
well
incub
min
room
temperatur
absorb
neutral
redstain
plate
read
nm
fulllength
human
gene
kindli
provid
dr
h
choe
harvard
medic
school
human
codonoptim
spike
gene
sarscov
vector
kindli
provid
dr
g
j
nabel
nation
institut
health
encod
luciferas
pactmyod
pbindid
plasmid
promega
use
fusion
assay
human
gene
spike
gene
sarscov
insert
clontech
respect
use
syncytium
format
assay
spike
gene
pbindid
plasmid
transfect
cell
lipofectamin
ltx
reagent
invitrogen
one
group
human
gene
pactmyod
transfect
cell
group
two
day
transfect
cell
express
protein
detach
trypsinedta
solut
sigma
edta
solut
cell
express
protein
detach
edta
solut
treatment
antisar
antibodi
perform
detach
cell
mix
cocultur
day
cell
harvest
lysi
buffer
centrifug
cell
lysat
mix
substrat
picagen
toyo
ink
luciferas
activ
measur
use
plate
reader
infinit
tecan
western
blot
analysi
cell
express
protein
treat
presenc
absenc
cell
detach
use
trypsinedta
edta
solut
antibodi
treatment
detach
cell
lyse
radioimmunoprecipit
assay
solut
sodium
dodecyl
sulfat
sodium
deoxychol
nonidet
p
mm
sodium
chlorid
mm
trishcl
ph
cell
lysat
separ
use
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
transfer
onto
immunblot
p
polyvinyliden
difluorid
membran
biorad
laboratori
membran
incub
mixtur
inhous
antibodi
describ
antirabbit
igg
horseradish
peroxidas
ge
healthcar
wash
membran
incub
supersign
west
substrat
thermo
scientif
accord
manufactur
instruct
spike
gene
gene
transfect
cell
separ
two
day
transfect
cell
express
protein
detach
trypsinedta
solut
edta
solut
hand
cell
express
protein
detach
edta
solut
cell
mix
cocultur
h
observ
olympu
microscop
procedur
approv
institut
anim
use
care
committe
institut
laboratori
anim
scienc
peke
union
medic
colleg
sham
administr
control
human
igg
administr
administr
group
rhesu
macaqu
year
age
use
experiment
infect
sarscov
spray
viru
median
cultur
tissu
infect
dose
nasal
caviti
anim
separ
describ
elsewher
antibodi
administ
intraven
h
viru
infect
day
infect
dose
mgkg
total
dose
mgkg
anim
sacrif
day
infect
lung
tissu
sampl
collect
organ
grossli
examin
photograph
record
lung
damag
haematoxylin
eosin
stain
tissu
section
detect
viral
antigen
determin
sarscov
load
reversetranscript
polymeras
chain
reaction
rtpcr
perform
describ
elsewher
preliminari
safeti
test
rhesu
model
aforement
group
rhesu
macaqu
without
sarscov
infect
use
test
antibodi
inject
intraven
time
interv
dose
mgkg
total
dose
mgkg
full
evalu
result
avail
upon
request
prepar
antigen
without
use
hazard
sarscov
use
recombin
protein
technolog
use
genom
sequenc
inform
gene
encod
sar
protein
obtain
commerci
servic
use
express
fragment
separ
supplement
fig
fragment
protein
base
function
domain
function
yet
assign
domain
respons
bind
contain
cleavag
site
viru
entri
bind
heptad
repeat
trimer
support
interact
respect
fragment
express
e
coli
histag
protein
purifi
homogen
use
tag
avoid
rais
antibodi
tag
tag
remov
enzymat
cleavag
ntermin
amino
acid
sequenc
analysi
confirm
cleavag
tag
expect
amino
acid
posit
fragment
obtain
evalu
abil
induc
neutral
antibodi
rabbit
supplement
fig
although
fragment
induc
antibodi
respons
use
antigen
vaccin
rabbit
fragment
induc
antibodi
neutral
sarscov
vitro
supplement
fig
basi
abil
induc
neutral
antibodi
fragment
use
vaccin
km
mice
obtain
fulli
human
mab
three
mab
reactiv
fragment
chosen
character
epitop
recogn
abil
neutral
sarscov
vitro
react
peptid
correspond
amino
acid
posit
protein
canlllqygsfctql
contrast
react
peptid
correspond
amino
acid
posit
protein
plkptkrsfiedllf
data
shown
latter
peptid
ident
recogn
serum
sampl
convalesc
patient
sar
vietnam
furthermor
amino
acid
trypsin
proteolyt
site
enhanc
fusion
viru
among
mab
show
vitro
sarscov
neutral
activ
effect
concentr
lgml
supplement
fig
result
indic
recogn
proteolyt
site
protein
potent
fulli
human
neutral
mab
sarscov
examin
mechan
sarscov
neutral
analyz
cellcel
fusion
sexpress
cell
cell
use
report
system
base
mammalian
system
cellcel
fusion
mediat
dualluciferas
report
system
activ
amount
cellcel
fusion
could
quantifi
treatment
trypsin
enhanc
cellcel
fusion
via
cleavag
site
locat
region
fusion
effici
cell
treat
edta
compar
cell
treat
edta
trypsin
presenc
absenc
figur
sexpress
cell
detach
cultur
dish
treatment
trypsin
addit
edta
cellular
fusion
reflect
rel
fluoresc
significantli
increas
comparison
detach
edta
cell
fusion
strongli
inhibit
human
igg
cell
treat
antibodi
detach
dish
contrast
show
inhibit
cell
fusion
ad
detach
dish
also
analyz
cellcel
fusion
mediat
interact
use
confoc
laser
microscopi
figur
sexpress
cell
cell
label
green
fluoresc
protein
dsred
respect
although
sexpress
cell
cell
partli
fuse
even
detach
edta
syncytium
format
strongli
enhanc
treatment
trypsin
addit
cell
mixtur
inhibit
syncytium
format
least
part
treat
without
trypsin
also
analyz
cleavag
trypsin
presenc
absenc
figur
trypsin
treatment
cleav
gener
addit
fragment
ca
kda
indic
arrow
addit
trypsin
treatment
significantli
affect
gener
fragment
furthermor
react
fragment
determin
western
blot
data
shown
suggest
uncleav
necessari
recognit
result
indic
inhibit
cellcel
fusion
step
cleavag
viru
propag
viru
replic
cycl
analyz
efficaci
anim
model
examin
whether
vitro
neutral
activ
sarscov
strain
isol
china
result
indic
neutral
strain
data
shown
analyz
efficaci
protect
sarscov
infect
rhesu
macaqu
anim
separ
group
animalsgroup
consist
sham
administr
control
igg
administr
administr
anim
infect
viru
strain
spray
nasal
caviti
antibodi
inject
intraven
h
viru
infect
day
infect
dose
mgkg
total
dose
mgkg
dose
mgkg
aim
archiv
inhibit
figur
inhibitori
effect
cellcel
fusion
mediat
interact
effect
cellcel
fusion
analysi
use
dualreport
system
fusion
sexpress
cell
human
cell
quantifi
describ
materi
method
cell
detach
without
trypsin
addit
edta
antibodi
treatment
perform
detach
indic
b
effect
syncytium
format
sexpress
cell
human
cell
syncytium
format
sand
cell
label
gfp
dsred
respect
visual
confoc
laser
microscopi
cell
detach
without
trypsin
addit
edta
mix
ad
cultur
indic
c
western
blot
analysi
determin
effect
cleavag
trypsin
treatment
sexpress
cell
treat
trypsin
edta
presenc
absenc
mgml
indic
lysi
cell
western
blot
use
anti
antibodi
mixtur
perform
control
cell
harbor
spike
gene
use
neg
control
concentr
blood
accord
result
vitro
sarscov
neutral
assay
gross
patholog
character
lung
day
anim
administ
show
signific
reduct
sever
damag
anim
comparison
sham
administr
group
figur
viral
load
lung
tissu
sampl
anim
analyz
use
realtim
rtpcr
rtpcr
day
infect
figur
realtim
rtpcr
analys
copi
sarscov
detect
lung
tissu
sampl
antisarsmab
administr
group
copi
sarscov
detect
lung
tissu
sampl
sham
administr
human
igg
administr
group
rtpcr
amplif
region
locat
polyprotein
sarscov
show
amplifi
fragment
sampl
shamadminist
anim
given
control
human
igg
amplif
fragment
observ
sampl
anim
result
indic
human
mab
almost
complet
abolish
persist
sarscov
rhesu
macaqu
model
vivo
immunohistochem
analysi
lung
tissu
section
stain
sarscov
antigen
develop
damino
benzidin
counterstain
perform
hematoxylin
figur
lung
tissu
sampl
anim
sham
administr
human
igg
administr
group
show
strong
reaction
sarscov
antigen
wherea
posit
reaction
viral
antigen
markedli
diminish
anim
administ
shown
figur
lung
tissu
sampl
infect
anim
sham
administr
group
show
typic
symptom
acut
diffus
alveolar
damag
dad
extens
exud
septal
broaden
shrinkag
alveoli
caus
pressur
restrict
fusion
thick
septa
ruptur
elast
fiber
alveoli
variabl
fill
proteinrich
edema
fluid
fibrin
erythrocyt
cellular
debri
moder
number
inflammatori
cell
alveolar
caviti
human
igg
administr
group
lung
mainli
show
typic
symptom
acut
dad
extens
exud
septal
broaden
shrinkag
alveoli
caus
pressur
restrict
fusion
thick
septa
ruptur
elast
fiber
alveoli
variabl
fill
proteinrich
edema
fluid
fibrin
erythrocyt
cellular
debri
moder
number
inflammatori
cell
alveolar
caviti
anim
extent
dad
slightli
milder
former
anim
contrast
lung
tissu
sampl
anim
administ
show
appar
inflamm
hemorrhag
septa
distort
elast
fiber
alveolar
wall
sign
earli
symptom
acut
dad
although
sign
markedli
diminish
comparison
tissu
sampl
former
group
patholog
find
summar
tabl
base
definit
sever
lung
damag
result
indic
fulli
human
mab
inhibit
viral
replic
amelior
patholog
chang
lung
sarscovinfect
rhesu
macaqu
safeti
administr
also
analyz
essenti
rhesu
model
describ
without
viral
infect
full
result
test
avail
request
expect
natur
fulli
human
antibodi
rhesu
monkey
administ
show
abnorm
behavior
pattern
examin
organ
kill
anim
show
safeti
concern
signific
amount
human
antisar
antibodi
detect
even
week
administr
data
shown
obtain
fulli
human
mab
show
high
sarscov
neutral
activ
vitro
vivo
rhesu
macaqu
model
knowledg
first
report
evalu
fulli
human
antibodi
sarscov
primat
model
epitop
identifi
amino
acid
posit
protein
sequenc
highli
conserv
among
sarscov
strain
patient
also
among
cov
strain
gener
contain
critic
cleavag
site
induc
exposur
fusion
peptid
cleavag
inhibit
cellcel
fusion
mediat
interact
even
presenc
trypsin
although
inhibit
effect
cell
treat
detach
trypsin
addit
edta
inde
effici
inhibit
cleavag
react
cleav
observ
suggest
prevent
viral
fusion
entri
host
cell
viral
attach
host
cell
cleavag
antibodi
recogn
epitop
locat
domain
induc
antibodydepend
enhanc
sarscov
entri
host
cell
amino
acid
sequenc
protein
chang
result
indic
target
protein
region
involv
mediat
viral
fusion
would
provid
feasibl
strategi
produc
neutral
antibodi
sarscov
robust
mutat
viru
synergist
effect
combin
mab
direct
toward
bind
domain
report
direct
toward
cleavag
site
may
serv
altern
combin
provid
stronger
synergist
effect
rhesu
macaqu
model
use
mirror
sequenc
pathogenesi
human
sar
clear
clinic
relev
model
observ
paramet
studi
elev
bodi
temperatur
lung
patholog
sarscov
antigen
detect
lung
tissu
sampl
indic
valuabl
model
evalu
candid
therapeut
agent
administr
significantli
suppress
sarscovinduc
pathogenesi
sar
rhesu
model
thu
suffici
effect
prevent
sarscov
infect
primat
model
signific
amount
human
antisar
antibodi
detect
even
week
administr
suffici
halflif
use
prophylaxi
therapeut
purpos
thu
promis
agent
use
reemerg
sar
taken
togeth
result
suggest
potenti
use
fulli
human
antibodybas
therapeut
sarscov
base
evalu
vivo
nonhuman
primat
model
studi
produc
use
recombin
protein
prepar
e
coli
express
system
studi
repres
platform
produc
fulli
human
antibodi
emerg
infecti
diseas
time
manner
recombin
protein
use
studi
contain
antigen
epitop
identifi
patient
serum
sampl
produc
e
coli
avoid
handl
larg
amount
hazard
sarscov
antigen
use
transgen
anim
produc
fulli
human
antibodi
make
possibl
rapidli
produc
fulli
human
antibodi
essenti
safe
clinic
applic
supplementari
data
avail
http
jidoxfordjournalsorg
onlin
work
support
nation
institut
biomed
innov
grant
japan
scienc
technolog
agenc
patholog
chang
lung
grade
base
follow
criteria
patholog
character
sever
lung
damag
sar
rhesu
macaqu
